title: Rapamycin potentiates the effects of paclitaxel in endometrial cancer cells through inhibition of cell proliferation and induction of apoptosis.
abstract: Mammalian target of rapamycin (mTOR) inhibitors modulate signaling pathways involved in cell cycle progression, and recent phase II trials demonstrate activity in patients with endometrial cancer. Our objective was to examine the effects of combination therapy with rapamycin and paclitaxel in endometrial cancer cell lines. Paclitaxel inhibited proliferation in a dose-dependent manner in both cell lines with IC(50) values of 0.1-0.5 nM and 1-5 nM for Ishikawa and ECC-1 cells, respectively. To assess synergy of paclitaxel and rapamycin, the combination index (CI) was calculated by the method of Chou and Talalay. Simultaneous exposure of cells to various doses of paclitaxel in combination with rapamycin (1 nM) resulted in a significant synergistic anti-proliferative effect (CI <1, range 0.131-0.920). Rapamycin alone did not induce apoptosis, but combined treatment with paclitaxel increased apoptosis over that of paclitaxel alone. Treatment with rapamycin and paclitaxel resulted in decreased phosphorylation of S6 and 4E-BP1, two critical downstream targets of the mTOR pathway. Rapamycin decreased hTERT mRNA expression by real-time RT-PCR while paclitaxel alone had no effect on telomerase activity. Paclitaxel increased polymerization and acetylation of tubulin, and rapamycin appeared to enhance this effect. Thus, in conclusion, we demonstrate that rapamycin potentiates the effects of paclitaxel in endometrial cancer cells through inhibition of cell proliferation, induction of apoptosis and potentially increased polymerization and acetylation of tubulin. This suggests that the combination of rapamycin and paclitaxel may be a promising effective targeted therapy for endometrial cancer.
authors.affiliation: Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of North Carolina, Chapel Hill, North Carolina 27599-7572, USA.
authors.forename: Aaron
authors.initials: A
authors.lastname: Shafer
authors.forename: Chunxiao
authors.initials: C
authors.lastname: Zhou
authors.forename: Paola A
authors.initials: PA
authors.lastname: Gehrig
authors.forename: John F
authors.initials: JF
authors.lastname: Boggess
authors.forename: Victoria L
authors.initials: VL
authors.lastname: Bae-Jump
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000494:pharmacology*; D017209:Apoptosis / Q000187:drug effects*; D015153:Blotting, Western; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects*; D004305:Dose-Response Relationship, Drug; D004357:Drug Synergism; D016889:Endometrial Neoplasms / Q000473:pathology*; D005260:Female; D006801:Humans; D020128:Inhibitory Concentration 50; D017239:Paclitaxel / Q000008:administration & dosage; D011494:Protein Kinases / Q000187:drug effects / Q000378:metabolism; D015398:Signal Transduction / Q000187:drug effects*; D020123:Sirolimus / Q000008:administration & dosage; D058570:TOR Serine-Threonine Kinases; D019098:Telomerase / Q000096:biosynthesis / Q000187:drug effects; D014404:Tubulin / Q000096:biosynthesis / Q000187:drug effects
chemical_list: D014404:Tubulin; D011494:Protein Kinases; C546842:MTOR protein, human; D058570:TOR Serine-Threonine Kinases; D019098:Telomerase; D017239:Paclitaxel; D020123:Sirolimus
references.citation: Cell. 2005 Mar 25;120(6):747-59
references.pmid: 15797377
references.citation: Br J Cancer. 2006 Jan 30;94(2):195-9
references.pmid: 16404421
references.citation: EMBO J. 1997 Jun 16;16(12):3693-704
references.pmid: 9218810
references.citation: Mol Cancer Ther. 2003 Aug;2(8):789-95
references.pmid: 12939469
references.citation: J Immunol. 1996 Jul 15;157(2):656-60
references.pmid: 8752914
references.citation: Cancer. 2009 Sep 1;115(17):3887-96
references.pmid: 19484784
references.citation: Semin Cancer Biol. 2000 Dec;10(6):399-406
references.pmid: 11170862
references.citation: Genes Dev. 2001 Apr 1;15(7):807-26
references.pmid: 11297505
references.citation: Expert Opin Investig Drugs. 2008 Dec;17(12):1947-54
references.pmid: 19012509
references.citation: Mol Cancer Ther. 2004 Dec;3(12):1605-13
references.pmid: 15634654
references.citation: Clin Cancer Res. 2007 Jul 15;13(14):4261-70
references.pmid: 17634556
references.citation: Curr Opin Cell Biol. 1998 Feb;10(1):123-30
references.pmid: 9484604
references.citation: Endocr Relat Cancer. 2003 Mar;10(1):23-42
references.pmid: 12653669
references.citation: Oncogene. 2004 Jul 29;23(34):5781-91
references.pmid: 15208671
references.citation: Drug Resist Updat. 2008 Jun;11(3):63-76
references.pmid: 18440854
references.citation: Crit Rev Oncol Hematol. 2006 Jun;58(3):242-56
references.pmid: 16436330
references.citation: Apoptosis. 2003 Oct;8(5):413-50
references.pmid: 12975575
references.citation: Gynecol Oncol. 2006 Mar;100(3):487-94
references.pmid: 16249016
references.citation: Gynecol Oncol. 1998 Feb;68(2):145-9
references.pmid: 9514809
references.citation: Endocr Relat Cancer. 2007 Sep;14(3):839-45
references.pmid: 17914112
references.citation: Oncol Rep. 1999 Jan-Feb;6(1):39-44
references.pmid: 9864398
references.citation: Clin Cancer Res. 2000 Feb;6(2):452-9
references.pmid: 10690523
references.citation: Curr Opin Immunol. 1998 Jun;10(3):330-6
references.pmid: 9638370
references.citation: Cancer Cell. 2007 Jul;12(1):9-22
references.pmid: 17613433
references.citation: Adv Enzyme Regul. 1984;22:27-55
references.pmid: 6382953
references.citation: Br J Cancer. 2004 Oct 18;91(8):1420-4
references.pmid: 15365568
references.citation: Oncogene. 2001 Sep 27;20(43):6172-80
references.pmid: 11593425
references.citation: Clin Cancer Res. 2004 Oct 15;10(20):7031-42
references.pmid: 15501983
references.citation: Gynecol Oncol. 2006 Apr;101(1):158-67
references.pmid: 16434086
references.citation: Mol Cancer. 2005 Jul 20;4(1):25
references.pmid: 16033649
references.citation: EMBO J. 1994 Mar 1;13(5):1205-15
references.pmid: 8131750
references.citation: Oncogene. 2003 Jan 30;22(4):484-97
references.pmid: 12555062
references.citation: Anticancer Res. 2004 Nov-Dec;24(6):3843-50
references.pmid: 15736420
references.citation: Gynecol Oncol. 2004 Sep;94(3):785-95
references.pmid: 15350374
references.citation: CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96
references.pmid: 18287387
references.citation: Mol Cancer Ther. 2002 Sep;1(11):937-41
references.pmid: 12481415
references.citation: Cancer Epidemiol Biomarkers Prev. 2007 Jul;16(7):1330-40
references.pmid: 17626998
references.citation: Proc Natl Acad Sci U S A. 2001 Aug 14;98(17):9666-70
references.pmid: 11493700
references.citation: Pharmacol Res. 2004 Dec;50(6):545-9
references.pmid: 15501691
references.citation: Cancer Res. 2001 Feb 15;61(4):1527-32
references.pmid: 11245461
references.citation: Cancer Res. 2003 Feb 1;63(3):579-85
references.pmid: 12566299
references.citation: Eur J Cancer. 2006 May;42(7):934-47
references.pmid: 16540312
references.citation: Gynecol Oncol. 1997 Jan;64(1):171-5
references.pmid: 8995569
references.citation: Cancer Chemother Pharmacol. 2008 Jul;62(2):305-13
references.pmid: 17912526